Deschatelets Pascal's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Jul 11, 2023
- Accession no.
- 0001127602-23-020575
- Filed
- Jul 11, 2023
- Trade date
- Jul 10, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.01M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deschatelets PascalCIK 0001657720 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2023 | Common Stock | MOption exerciseAcquired | +18,500 | $2.67 | +$49,395 | 1,058,813 | Direct | |
| Jul 10, 2023 | Common Stock | SSaleDisposed | −12,000 | $84.55 | −$1,014,600 | 1,046,813 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2023 | Common Stock | MOption exerciseDisposed | −18,500 | $0.00 | $0 | 72,994 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.